Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARVN NASDAQ:LGND NASDAQ:SDGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$10.11-0.8%$11.43$5.90▼$14.51$657.43M1.79784,757 shs593,968 shsLGNDLigand Pharmaceuticals$221.41+5.3%$212.17$98.89▼$247.38$4.21B1.2237,064 shs249,976 shsSDGRSchrodinger$13.13-1.1%$12.09$10.94▼$27.63$980.40M1.571.62 million shs1.78 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas0.00%+2.93%-9.10%-24.41%+53.58%LGNDLigand Pharmaceuticals0.00%-8.33%+1.08%+10.44%+99.14%SDGRSchrodinger0.00%+11.04%+15.48%-1.56%-44.03%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$10.11-0.8%$11.43$5.90▼$14.51$657.43M1.79784,757 shs593,968 shsLGNDLigand Pharmaceuticals$221.41+5.3%$212.17$98.89▼$247.38$4.21B1.2237,064 shs249,976 shsSDGRSchrodinger$13.13-1.1%$12.09$10.94▼$27.63$980.40M1.571.62 million shs1.78 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas0.00%+2.93%-9.10%-24.41%+53.58%LGNDLigand Pharmaceuticals0.00%-8.33%+1.08%+10.44%+99.14%SDGRSchrodinger0.00%+11.04%+15.48%-1.56%-44.03%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARVNArvinas 2.40Hold$14.8646.95% UpsideLGNDLigand Pharmaceuticals 2.88Moderate Buy$257.7116.40% UpsideSDGRSchrodinger 2.33Hold$20.5056.13% UpsideCurrent Analyst Ratings BreakdownLatest ARVN, LGND, and SDGR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026LGNDLigand Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$252.00 ➝ $262.005/4/2026ARVNArvinas CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$21.00 ➝ $24.005/1/2026LGNDLigand Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Hold (C+)4/30/2026LGNDLigand Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$243.00 ➝ $289.004/28/2026LGNDLigand Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$235.00 ➝ $252.004/27/2026ARVNArvinas Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/15/2026LGNDLigand Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$276.00 ➝ $282.004/14/2026LGNDLigand Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$239.00 ➝ $243.004/10/2026ARVNArvinas Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/8/2026SDGRSchrodinger KeyCorpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$25.00 ➝ $20.003/24/2026LGNDLigand Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$270.00 ➝ $276.00(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARVNArvinas$262.60M2.48N/AN/A$6.76 per share1.50LGNDLigand Pharmaceuticals$268.09M16.55$8.26 per share26.79$49.77 per share4.45SDGRSchrodinger$255.87M3.79N/AN/A$4.25 per share3.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARVNArvinas-$80.80M-$1.28N/AN/AN/A-30.77%-14.25%-9.31%5/12/2026 (Estimated)LGNDLigand Pharmaceuticals$124.45M$5.8330.0429.561.7155.95%16.19%11.13%5/14/2026 (Estimated)SDGRSchrodinger-$103.26M-$1.41N/AN/AN/A-40.61%-30.85%-15.32%N/ALatest ARVN, LGND, and SDGR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026LGNDLigand Pharmaceuticals$1.84$1.63-$0.21-$0.67$59.10 million$51.72 million5/12/2026Q1 2026ARVNArvinas-$0.95N/AN/AN/A$16.61 millionN/A5/5/2026Q1 2026SDGRSchrodinger-$0.56-$0.81-$0.25-$0.81$47.57 million$58.59 million2/26/2026Q4 2025LGNDLigand Pharmaceuticals$1.46$2.02+$0.56$2.12$55.59 million$59.67 million2/25/2026Q4 2025SDGRSchrodinger-$0.13$0.44+$0.57$0.44$83.66 million$87.24 million2/24/2026Q4 2025ARVNArvinas-$0.55-$1.10-$0.55-$1.10$37.26 million$9.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARVNArvinasN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/ASDGRSchrodingerN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARVNArvinasN/A4.924.92LGNDLigand Pharmaceuticals0.4521.2821.98SDGRSchrodingerN/A2.742.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARVNArvinas95.19%LGNDLigand Pharmaceuticals91.28%SDGRSchrodinger79.05%Insider OwnershipCompanyInsider OwnershipARVNArvinas4.73%LGNDLigand Pharmaceuticals7.00%SDGRSchrodinger21.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARVNArvinas42064.52 million61.47 millionOptionableLGNDLigand Pharmaceuticals8020.04 million18.64 millionOptionableSDGRSchrodinger79073.82 million58.32 millionOptionableARVN, LGND, and SDGR HeadlinesRecent News About These CompaniesSchrodinger (NASDAQ:SDGR) Downgraded to Strong Sell Rating by Wall Street ZenMay 9 at 2:35 AM | marketbeat.comEarnings Update: Schrödinger, Inc. (NASDAQ:SDGR) Just Reported And Analysts Are Trimming Their ForecastsMay 8 at 8:57 AM | finance.yahoo.comSchrödinger (SDGR) Q1 2026 Earnings TranscriptMay 6 at 8:23 PM | finance.yahoo.comA Look At Schrödinger (NasdaqGS:SDGR) Valuation After Q1 Earnings And Hosted AI Software PushMay 6 at 8:23 PM | finance.yahoo.comSchrödinger, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 6 at 1:01 AM | seekingalpha.comSchrodinger Q1 Earnings Call HighlightsMay 5, 2026 | marketbeat.comSchrödinger, Inc. (SDGR) Q1 2026 Earnings Call TranscriptMay 5, 2026 | seekingalpha.comSchrödinger Earnings Call: Growth Now, Profits LaterMay 5, 2026 | tipranks.comSchrodinger, Inc. (SDGR) Reports Q1 Loss, Misses Revenue EstimatesMay 5, 2026 | zacks.comSchrodinger (NASDAQ:SDGR) Issues Earnings ResultsMay 5, 2026 | marketbeat.comSchrödinger Reports First Quarter 2026 Financial ResultsMay 5, 2026 | businesswire.comHere’s What the Street Thinks About Schrödinger (SDGR)May 5, 2026 | insidermonkey.comSchrodinger (NASDAQ:SDGR) Trading Up 5.8% - Here's WhyApril 28, 2026 | marketbeat.comSchrodinger (SDGR) Projected to Post Quarterly Earnings on TuesdayApril 28, 2026 | marketbeat.comSchrodinger: AI Threat Is Looming Large (Rating Downgrade)April 22, 2026 | seekingalpha.comSchrodinger, Inc. (NASDAQ:SDGR) Given Average Recommendation of "Hold" by BrokeragesApril 22, 2026 | marketbeat.comSchrödinger to Announce First Quarter 2026 Financial Results on May 5April 21, 2026 | businesswire.comWhat’s Schrodinger Inc (SDGR) Working Out with Anthropic?April 19, 2026 | finance.yahoo.comSchrodinger (NASDAQ:SDGR) CFO Sells $10,761.00 in StockApril 18, 2026 | insidertrades.comSchrodinger (NASDAQ:SDGR) CFO Rachit Jain Sells 844 SharesApril 17, 2026 | marketbeat.comRamy Farid Sells 43,000 Shares of Schrodinger (NASDAQ:SDGR) StockApril 17, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARVN, LGND, and SDGR Company DescriptionsArvinas NASDAQ:ARVN$10.11 -0.08 (-0.79%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$10.01 -0.10 (-0.98%) As of 05/8/2026 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Ligand Pharmaceuticals NASDAQ:LGND$221.41 +11.08 (+5.27%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$221.16 -0.25 (-0.11%) As of 05/8/2026 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.Schrodinger NASDAQ:SDGR$13.13 -0.15 (-1.13%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$13.23 +0.10 (+0.78%) As of 05/8/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
